Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in July 2018.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2zEngPG
via IFTTT
Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in July 2018.
No comments:
Post a Comment